MARA Rating’s Care Pathway Integration score (A++–C) predicts HTA endorsement and payer adoption by measuring clinical guideline alignment, workflow efficiency, administration ease, and implementation feasibility.
Too often, M&A teams under-weight operational hurdles—care-pathway integration can make or break HTA endorsement. Since 2020, assets averaging a 3.3 Care Pathway Integration score secured smoother payer adoption, while those at 3.1 faced implementation caveats. That 0.2-point gap defines whether your therapy is a plug-and-play solution—or a workflow burden.
What Is Care Pathway Integration?
- Alignment with Clinical Guidelines – Is your indication embedded in national or regional treatment pathways?
- Ease of Administration – Do dosing schedules, monitoring protocols and delivery formats fit routine practice?
- Workflow Efficiency – Are additional staff, infrastructure or training requirements minimal?
- Multidisciplinary Coordination – Does your therapy enable seamless hand-offs among specialists, nurses and primary care?
Strong vs. Marginal Scores
- A++ / A+ / A (≥3.3): Recognized as straightforward to implement, with limited disruption to existing care pathways.
- B++ to C (≤3.1): Triggered requests for pilot programs, implementation studies or budget-impact analyses.
Actionable Best Practices
- Market Access Teams: Engage clinical and operations early—map training, monitoring and infrastructure needs.
- Investors & Acquirers: Prioritize assets with low operational burden to de-risk roll-out.
- Drug Developers: Optimize formulation and dosing for usability; run integration pilots in representative centers.
Explore 350+ independent assessments in our online catalogue: https://mararating.com/mara-ratings-list
Follow MARA Rating for more independent HTA insights: linkedin.com/company/mara-rating-company
#MarketAccessRiskAssessment #HTAAssessment #CarePathwayIntegration #ImplementationFeasibility #MARARating #WorkflowEfficiency